<DOC>
	<DOCNO>NCT00915954</DOCNO>
	<brief_summary>Growth hormone ( GH ) Insulin-like growth factor-I ( IGF-I ) secretion alter acromegaly type 2 Diabetes Mellitis ( DM ) . The secretion GH mediate central hypothalamic hormone ( GH Releasing Hormone somatostatin ) well peripheral factor provide feedback inhibition ( IGF-I glucose , among others ) . The purpose study compare growth hormone suppression oral glucose tolerance test ( OGTT ) growth hormone suppression recombinant human IGF-I ( rhIGF-I ) administration . This study recruit participant active acromegaly , type 2 diabetes mellitus , healthy control subject . Each participant undergo screen evaluation , three subsequent visit . Each participant receive placebo subcutaneous injection , OGTT , administration rhIGF-I , separate visit day . Glucose , insulin , GH , bioactive IGF-I IGF-I binding protein measure intervention . Results compare three group . It predict administration rhIGF-I demonstrate GH suppression healthy subject subject type 2DM . Some acromegaly subject may demonstrate GH suppression response IGF-I administration , degree see healthy subject type 2 DM . OGTT demonstrate suppression GH normal subject , show attenuated suppression type 2 DM failure suppression acromegaly .</brief_summary>
	<brief_title>Growth Hormone Feedback Insulin-like Growth Factor-I ( IGF-1 ) Oral Glucose Tolerance Test ( OGTT )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Active acromegaly due excess GH produce pituitary adenoma . Patients must elevate IGFI compare age gender match control ( supplied laboratory ) fail suppress GH 1 ng/ml standard 75g oral glucose tolerance test . Type 2 diabetes mellitus , define elevate fast glucose ≥ 126 mg/dl ( verified two historical measurement ) , plasma glucose ≥ 200 mg/dl two hour 75 g oral glucose load , random glucose ≥ 200 mg/dl . 1 . Acromegaly Group Current medical therapy acromegaly include dopamine agonist , somatostatin analogue , growth hormone antagonist . For subject current therapy follow washout period may use : Cabergoline : 4 week Bromocriptine : 1 week Sandostatin LAR : 3 month Shortacting octreotide : 1 week Lanreotide : 3 month Pegvisomant : 4 week Subjects history surgical therapy treatment acromegaly must verification active disease verify elevated IGFI subject ' age gender compare healthy control ( supplied laboratory ) ( two measure ) well failure suppress GH 1 ng/ml OGTT . Current treatment insulin resistance type 2 DM include oral injection medication . Fasting glucose ≥ 126 mg/dl screen evaluation . Evidence hepatic renal disease define elevated transaminase , elevate serum creatinine . Pregnancy breast feed . 2 . Type 2 diabetes mellitus group Patients take noninsulin medication diabetes treatment exclude . Diagnosis acromegaly . Evidence hepatic renal disease define elevated transaminase , elevate serum creatinine . Pregnancy breast feed . 3 . Healthy Control Group History diabetes mellitus impaired glucose tolerance , history acromegaly . Fasting glucose ≥ 126 mg/dl screen evaluation . Evidence hepatic renal disease define elevated transaminase , elevate serum creatinine . Pregnancy breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>recombinant human IGF1</keyword>
	<keyword>oral glucose tolerance test</keyword>
</DOC>